Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Approval of brentuximab vedotin for CD30+ mycosis fungoides

Pablo Ortiz Romero • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Brentuximab vedotin

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, talks on the use of brentuximab vedotin, an antibody-drug conjugate which is approved for the treatment of mycosis fungoides, a subtype of cutaneous T-cell lymphoma, who are CD30+. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Pablo Ortiz Romero

1:05
RESMAIN: resmonistat for CTCL maintenance
Pablo Ortiz Romero • 14 Oct 2021
1:13
Novel therapies on the horizon for CTCL
Pablo Ortiz Romero • 14 Oct 2021
1:23
Pegylated liposomal doxorubicin as maintenance in mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
0:38
Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab
Pablo Ortiz Romero • 14 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals